help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Postema, P. T.
Right arrow Articles by van der Loos, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Postema, P. T.
Right arrow Articles by van der Loos, T.

Journal of Clinical Endocrinology & Metabolism, Vol 79, 1845-1851, Copyright © 1994 by Endocrine Society

ARTICLES

[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

PT Postema, EP Krenning, R Wijngaarde, PP Kooy, HY Oei, WA van den Bosch, JC Reubi, WM Wiersinga, H Hooijkaas and T van der Loos
Department of Internal Medicine III, Erasmus University Hospital, Rotterdam, The Netherlands.

Visualization of malignant lymphomas and granulomatous disease is possible by [111In-DTPA-D-Phe1]octreotide scintigraphy through binding of the radioligand to somatostatin receptors on activated leukocytes. Because thyroidal and orbital tissues are infiltrated by activated leukocytes in Graves' disease, a cross-sectional study to visualize disease activity with [111In-DTPA-D-Phe1]octreotide scintigraphy was performed. A correlation between thyroidal [111In-DTPA-D- Phe1]octreotide accumulation and free T4 (disease expression) and thyroid binding-inhibiting immunoglobulins (disease activity) is present in untreated hyperthyroid Graves' disease. There is also a correlation between orbital [111In-DTPA-D-Phe1]octreotide uptake and the clinical activity score (disease activity) and total eye score (disease expression), respectively, in Graves' orbitopathy. Visualization of thyroidal and orbital Graves' disease is feasible, but further investigation is necessary to establish the role of [111In-DTPA- D-Phe1]octreotide scintigraphy in representing disease activity and expression and in predicting therapeutical outcome.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
I. Cozma, L. Zhang, J. Uddin, C. Lane, A. Rees, and M. Ludgate
Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1630 - E1635.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Savastano, R. Pivonello, W. Acampa, M. Salvatore, G. Lombardi, A. Colao, and G. Fenzi
Recombinant Thyrotropin-Induced Orbital Uptake of [111In-Diethylenetriamine-Pentacetic Acid-D-Phe1]Octreotide in a Patient with Inactive Graves' Ophthalmopathy
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2440 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Wemeau, P. Caron, A. Beckers, V. Rohmer, J. Orgiazzi, F. Borson-Chazot, M. Nocaudie, P. Perimenis, S. Bisot-Locard, I. Bourdeix, et al.
Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves' Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 841 - 848.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. J. Dickinson, B. Vaidya, M. Miller, A. Coulthard, P. Perros, E. Baister, C. D. Andrews, L. Hesse, J. T. Heverhagen, A. E. Heufelder, et al.
Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5910 - 5915.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Pasquali, A. Notaro, G. Bonavolonta', P. Vassallo, A. Bellastella, and A. A. Sinisi
Somatostatin Receptor Genes Are Expressed in Lymphocytes from Retroorbital Tissues in Graves' Disease
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5125 - 5129.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Kwekkeboom, E. P. Krenning, and M. de Jong
Peptide Receptor Imaging and Therapy
J. Nucl. Med., October 1, 2000; 41(10): 1704 - 1713.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Bartalena, A. Pinchera, and C. Marcocci
Management of Graves' Ophthalmopathy: Reality and Perspectives
Endocr. Rev., April 1, 2000; 21(2): 168 - 199.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, S. Lastoria, D. Ferone, R. Pivonello, P. E. Macchia, P. Vassallo, G. BonavolontÁ, P. Muto, G. Lombardi, and G. Fenzi
Orbital Scintigraphy with [111In-Diethylenetriamine Pentaacetic Acid-D-Phe1]-Octreotide Predicts the Clinical Response to Corticosteroid Therapy in Patients with Graves' Ophthalmopathy
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3790 - 3794.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society